A study led by Roswell Park provides new insight into the complex interactions of the “tumor-immune-gut axis,” and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient’s microbiome — the collection of microorganisms in the body —and lay the groundwork for future clinical trials aimed at improving treatment outcomes.

Among the highlights of Roswell Park presentations at the 2024 San Antonio Breast Cancer Symposium are a special session moderated by Christine Ambrosone, PhD, focused on helping patients and survivors to cut through the confusion and conflicting evidence on exercise and lifestyle factors.

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax.

In a talk at the 66th American Society of Hematology Annual Meeting, researchers from Roswell Park are presenting compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma.

The results of two important lymphoma studies led by experts at Roswell Park will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.

Research led by Roswell Park's Dr. Matthew Cortese has shed light on how the drug venetoclax works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S.

A preclinical study led by Roswell Park faculty member Lisa Niswander, MD, PhD, shows that gilteritinib can strengthen CAR T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates.